A new study from the BC Centre for Excellence in HIV/AIDS (BC-CfE) shows highly active antiretroviral therapy (HAART) reduces new HIV diagnoses, deaths and HIV prevalence, suggesting that the made-in-Canada Treatment as Prevention strategy should be implemented across the country.
HIV-positive individuals who strictly adhere to highly active antiretroviral therapy (HAART) have a significantly lower probability of premature morbidity and mortality as compared to those with suboptimal compliance to HAART, according to a new study from the BC Centre for Excellence in HIV/AIDS (BC-CfE).
Researchers with the Neglected Global Diseases Initiative (NGDI) at the University of British Columbia have attracted more than $20 million in funding to find ways to eliminate diseases and conditions that kill millions of people in developing countries worldwide.
A drug delivery system developed through the University of British Columbia’s Neglected Global Diseases Initiative and licensed to iCo Therapeutics Inc. will receive $1.1 million from the National Research Council of Canada (NRC) for clinical development as a treatment for HIV patients.
Daniel Werb, senior research assistant at the Addiction and Urban Health Research Initiative (UHRI) at the BC Centre for Excellence in HIV/AIDS (BC-CfE), has been awarded the 2012 Pierre Elliott Trudeau Foundation Doctoral Scholarship for his PhD research project investigating initiation and cessation of injection drug use among street youth in Vancouver.
An independent reviewer has dismissed concerns over a study that shows a 35-per-cent decrease in overdose deaths after the opening of Insite, North America’s only supervised injection facility.
